ID

17190

Descrizione

Lingzhi and Sen Miao San for the Treatment of Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT00432484

collegamento

https://clinicaltrials.gov/show/NCT00432484

Keywords

  1. 30/08/16 30/08/16 -
Caricato su

30 agosto 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Rheumatoid Arthritis NCT00432484

Eligibility Rheumatoid Arthritis NCT00432484

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
fulfilled the 1987 american college of rheumatology (acr) criteria for ra.
Descrizione

Rheumatoid Arthritis

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0003873
the presence of 2 or more swollen or tender joints, based on 28-joint count.
Descrizione

swollen/tender joint count

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0451521
UMLS CUI [2]
C0451530
morning stiffness lasting for 30 minutes.
Descrizione

morning stiffness

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0457086
erythrocyte sedimentation rate (esr) of 28 mm/hour, despite treatment with disease modifying agent including mtx, sulphasalazine, hydroxychloroquine, auranofin or azathioprine were recruited into the study.
Descrizione

erythrocyte sedimentation rate (esr), treatment with disease modifying agent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1176468
UMLS CUI [2]
C0242708
patients taking glucocorticoids (prednisone < 7.5 mg/day) and/or nonsteroidal antiinflammatory drugs must have been taking a stable dosage for at least 4 weeks before entering the trial and were required to take the same dosage throughout the trial.
Descrizione

glucocorticoids and/or nonsteroidal antiinflammatory drugs, stable dosage

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0017710
UMLS CUI [1,2]
C0205360
UMLS CUI [2,1]
C0003211
UMLS CUI [2,2]
C0205360
patients had radiographic erosive diseases.
Descrizione

Bone erosion

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0587240
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who are pregnant or nursing mothers.
Descrizione

pregnant or breast feeding

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
severe liver disease (e.g cirrhosis, chronic active hepatitis)
Descrizione

Severe liver disease

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0023895
UMLS CUI [1,2]
C0205082
renal impairment (serum creatinine level > 150mmol/l)
Descrizione

serum creatinine

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0201976
known hypersensitivity to herbal medicine
Descrizione

Hypersensitivity to herbal medicine

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0025125

Similar models

Eligibility Rheumatoid Arthritis NCT00432484

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Rheumatoid Arthritis
Item
fulfilled the 1987 american college of rheumatology (acr) criteria for ra.
boolean
C0003873 (UMLS CUI [1])
swollen/tender joint count
Item
the presence of 2 or more swollen or tender joints, based on 28-joint count.
boolean
C0451521 (UMLS CUI [1])
C0451530 (UMLS CUI [2])
morning stiffness
Item
morning stiffness lasting for 30 minutes.
boolean
C0457086 (UMLS CUI [1])
erythrocyte sedimentation rate (esr), treatment with disease modifying agent
Item
erythrocyte sedimentation rate (esr) of 28 mm/hour, despite treatment with disease modifying agent including mtx, sulphasalazine, hydroxychloroquine, auranofin or azathioprine were recruited into the study.
boolean
C1176468 (UMLS CUI [1])
C0242708 (UMLS CUI [2])
glucocorticoids and/or nonsteroidal antiinflammatory drugs, stable dosage
Item
patients taking glucocorticoids (prednisone < 7.5 mg/day) and/or nonsteroidal antiinflammatory drugs must have been taking a stable dosage for at least 4 weeks before entering the trial and were required to take the same dosage throughout the trial.
boolean
C0017710 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C0003211 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
Bone erosion
Item
patients had radiographic erosive diseases.
boolean
C0587240 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
pregnant or breast feeding
Item
patients who are pregnant or nursing mothers.
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
Severe liver disease
Item
severe liver disease (e.g cirrhosis, chronic active hepatitis)
boolean
C0023895 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
serum creatinine
Item
renal impairment (serum creatinine level > 150mmol/l)
boolean
C0201976 (UMLS CUI [1])
Hypersensitivity to herbal medicine
Item
known hypersensitivity to herbal medicine
boolean
C0020517 (UMLS CUI [1,1])
C0025125 (UMLS CUI [1,2])

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial